Cancer care: review of upper GI cancer quality performance indicators - consultation

Page 1 of 5

Closes 13 Feb 2023

Questions

QPI 1: Endoscopy. Patients with oesophageal or gastric cancer should undergo endoscopy and biopsy to reach a diagnosis of cancer.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 3: Multi-Disciplinary Team Meeting. Patients should be discussed by a multidisciplinary team prior to definitive treatment.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 4: Staging and Treatment Intent. Patients with oesophageal or gastric cancer should be staged using the TNM staging system and have statement of treatment intent recorded prior to treatment commencing.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 5: Nutritional Assessment. Patients with oesophageal or gastric cancer should be appropriately assessed by a dietitian to optimise nutritional status.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 6: Appropriate Selection of Surgical Patients. Patients with oesophageal or gastric cancer whose treatment plan is neoadjuvant chemotherapy or chemoradiotherapy followed by surgery should progress to surgery following completion of this treatment.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 7: 30/90 Day Mortality Following Surgery. 30 and 90 day mortality following surgical resection for oesophageal or gastric cancer.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 8: Lymph Node Yield. For patients with oesophageal or gastric cancer undergoing curative resection the number of lymph nodes examined should be maximised.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 9: Length of Hospital Stay Following Surgery. Length of hospital stay following surgery for oesophageal or gastric cancer should be as short as possible.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 10: Resection Margins. Oesophageal and gastric cancers which are surgically resected should be adequately excised.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 11: Curative Treatment Rates. Patients with oesophageal or gastric cancer should undergo curative treatment whenever possible.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 13: HER2 Status for Decision Making. HER2 status should be available to inform treatment decision making in patients with oesophageal or gastric adenocarcinoma.

Please provide comments on this QPI in the box below if relevant for you to do so. 

W

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)
QPI 15: PD-L1 Status for Decision Making. PD-L1 status should be available to inform treatment decision making in patients with oesophageal or gastric cancer.

Please provide comments on this QPI in the box below if relevant for you to do so. 

We are interested in hearing your views on:

  • the appropriateness of the QPI
  • the target level that have been set
  • feasibility of measuring the QPI identified in a meaningful and comparative way (i.e. ‘like for like’ comparison)